We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PJT:NYSEPJT Partners Inc. Analysis

Data as of 2026-07-29 - not real-time

$170.23

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

PJT Partners is trading at $170.23, comfortably above its 20‑day (~$162) and 50‑day (~$158) moving averages, signaling short‑term strength. The MACD line sits above its signal with a positive histogram, and the RSI at 60 reinforces a bullish but not overbought stance. Volatility remains elevated at roughly 44% over the past month, while beta near 0.93 suggests price moves are slightly less volatile than the market. Fundamentally, the firm posted 28.9% revenue growth, a 95% gross margin and a 37% ROE, underscoring a high‑quality earnings engine. A discounted cash‑flow model values PJT near $399, implying roughly 45% upside versus the current price, and the modest 0.59% dividend with a 14% payout ratio appears sustainable. Recent news of PJT being named financial adviser to Genel Energy’s cash acquisition and a bullish analyst rating further boost sentiment.
However, trading volume has been tapering, and the stock sits about $6 below the identified resistance around $176, leaving short‑term upside capped. The upcoming Q2 earnings release adds a near‑term catalyst that could swing sentiment either way. The capital‑markets sector carries medium cyclical risk, but regulatory and geographic exposures are limited. Overall, the blend of strong profitability, attractive valuation gap, and dividend sustainability positions PJT as a compelling long‑run buy despite short‑term volatility. Investors should monitor earnings guidance and deal flow to gauge momentum.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Bullish MACD and RSI indicating momentum
  • Advisory win with Genel Energy adding deal flow confidence
  • Undervaluation relative to DCF fair value

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Upcoming earnings release creates near‑term uncertainty
  • Strong revenue growth and high margins sustain outlook
  • Elevated volatility and decreasing volume temper optimism

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • High ROE and consistent profitability
  • Significant upside potential versus current price
  • Sustainable dividend with low payout ratio

Key Metrics & Analysis

Financial Health

Revenue Growth28.90%
Profit Margin10.33%
P/E Ratio23.2
ROE37.04%
ROA21.94%
Debt/Equity45.34
P/B Ratio16.2
Op. Cash Flow$666.5M
Industry P/E18.1

Technical Analysis

TrendNeutral
RSI60.3
Support$142.47
Resistance$176.35
MA 20$162.51
MA 50$158.43
MA 200$160.86
MACDBullish
VolumeDecreasing
Fear & Greed Index87.14

Valuation

Fair Value$399.03
Target Price$171.00
Upside/Downside0.45%
GradeUndervalued
TypeGrowth
Dividend Yield0.59%

Risk Assessment

Beta0.93
Volatility44.21%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.